Vacc-4x shows statictically significant reduction in viral load

Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo – Bionor Pharma reverses decision to put Vacc-4x on hold

Independent research report on Bionor published in Thomson Reuters' "Current Opinion in Investigational Drugs"

To view the research report in its entirety, please follow the link.

Henrik Lund MD Ph.D Named as New CEO

Henrik Lund MD Ph.D, Former Global VP of Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA

Financial Times: HIV / Aids: Discordant visions.

Changing outlook: demonstrators in Cape Town last year raise fears about finance for action to combat the virus. But in contrast to past wariness, South Africa sent its vice-president and minister of health to tell this week’s Vienna conference of a redoubled prevention, testing and treatment effort. The country has one of the highest HIV burdens

Results of Vacc-4x HIV vaccine announced

Researchers with the Oslo University and Bionor Immuno at the XVIII International AIDS Conference in Vienna, Austria, recently released the results of a re-vaccination study of Norway’s largest hospital using the company's furthest advance HIV vaccine candidate, Vac-4x

Reuters: Many forks loom in road to AIDS vaccine

(Reuters) - AIDS experts and advocates gathering in Vienna this weekend for a conference on the pandemic will hear about progress in protecting people from the deadly virus using drugs, and ways to affect behavio

Changed Financial Calendar 2010

Bionor Immuno Researchers Discover Pathway that Allows HIV “Natural Viral Suppressors” to Live Without Symptoms; Study Findings Confirm Potential for Vacc-C5

A study performed in collaboration with the University of Maryland School of Medicine’s Institute for Human Virology leads Bionor Immuno researchers to believe they have found a way to replicate the immune responses previously associated with “natural viral suppressors,” those people who are able naturally to control HIV without medication, the Company announced today

Bionor Pharma's re-vaccination study accepted as a poster at the XVIII International AIDS conference

Bionor Pharma's subsidiary, Bionor Immuno AS recently carried out a
re-vaccination study at Norway's largest hospital, using Vacc-4x, the company's
most advanced HIV-vaccine candidate

Nutri Pharma ASA to change name to Bionor Pharma ASA

On 19 May 2010 Nutri Pharma ASA's Annual General Meeting resolved to change the company name from Nutri Pharma ASA to Bionor Pharma ASA.

NutriPharma ASA and subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting

27.05.2010 - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known as Bionor Pharma ASA

Minutes from the Annual General Meeting of Nutri Pharma ASA

19.05.2010 - Nutri Pharma ASA´s Annual General Meeting was held today, 19 May 2010. All proposed resolutions in the notice to the meeting were approved by the shareholders

Ny CFO i Nutri Pharma ASA

06.05.2010 - Rolf Henning Lem er ansatt som ny CFO i Nutri Pharma ASA. Rolf Henning skal, i tillegg til de funksjoner som ligger under CFO-stillingen, bistå aktivt i arbeidet med å kommersialisere Bionor Immunos teknologiske plattform mot farmasiselskaper internasjonalt

Invitation to the Annual General Meeting

28.04.2010 - The Annual General Meeting of Nutri Pharma ASA will be held on Wednesday 19 May 2010, 10:00 a.m. at the company's offices at Kronprinsesse Märthas plass 1

Extraordinary shareholders meeting

07.04.2010 - Nutri Pharma ASA has today sent the attached notice to shareholders of the company

Innkalling til Ekstraordinær Generalforsamling

05.04.2010 - Det innkalles herved til ekstraordinær generalforsamling i Nutri Pharma ASA den 28.april 2010 klokken 10.00 på selskapets forretningskontor i Kronprinsesse Märtas Plass 1 i Osl

CHANGES TO THE BOARD OF DIRECTORS OF NUTRI PHARMA ASA

05.04.2010 - Thorleif Krarup, chairman of the board of directors of Nutri Pharma ASA (ticker "NUT") has informed that he wishes to resign from his position as chairman of the board

New path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers

16.03.2010 - Vacc-C5 to Move from Lab to Phase I/II Clinical Trial. Based on encouraging results from pre-clinical research, Bionor Immuno AS, today announced intentions to take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 into a Phase I/II clinical trial

Completion of Subsequent Offering

08.03.2010 - Reference is made to the prospectus dated 18 February 2010 regarding the subsequent offering of up to 10,000,000 Subsequent Offering Shares in Nutri Pharma ASA ("Nutri Pharma") to a price of NOK 2.00 per share, constituting gross proceeds of up to NOK 20,000,000 (the "Subsequent Offering")

Approved supplemental prospectus

26.02.2010 - Oslo Børs has approved following supplemental prospectus:
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

FOURTH QUARTER AND PRELIMINARY 2009 RESULTS

23.02.2010 - Turnover from sale to Nikken was for FY 2009 MNOK 14.1. Nikken topped up its inventories in conjunction with the launch in May 2009

New Primary insiders in NUT 19 February 2010

19.02.2010 - Reference is made to the stock exchange notification published by 18 February 2010 regarding primary insiders in Nutri Pharma ASA ("NUT")

Commencement of subscription period for subsequent offering

19.02.2010 - Reference is made to stock exchange notice 18 February 2010 regarding completion of private placement in Nutri Pharma ASA ("NUT" or the "Company") of 50 million shares (the "Private Placement") as well as previous stock exchange notices

Share capital increase and registrations in the Norwegian Register of Business Enterprises

18.02.2010 - Reference is made to the stock exchange notice of 12 February 2010 regarding the extraordinary general meeting of Nutri Pharma ASA (the "Company")